Cerevel Therapeutics Holdings, Inc.
CERE · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $7 | $5 | $4 | $2 |
| - Cash | $1 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $6 | $5 | $4 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.67 | -2.32 | -1.63 | -1.29 |
| % Growth | -15.1% | -42.3% | -26.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |